| Name | CAS No. | Usage | Status |
| Eltrombopag Olamine | 496775-62-3 | Low Blood | US DMF 38914 |
| Platelet Count | NMPA Approval Y20230000603 | ||
| Trametinib(DMSO) | 1187431-43-1 | Melanoma | Validation & Registration in 2025 |
| Dabrafenib Mesylate | 1195768-06-9 | Melanoma | Validated |
|
WC Available |
|||
| Ibrutinib(Form A) | 936563-96-1 | Leukemia (CLL/MCL) | NMPA CDE |
| Y20230001268 | |||
| Tepotinib | 1100598-32-0 | NSCLC | Validated & registration in 2025 |
| Hydrochloride | 1946826-82-9 | ||
| Etrasimod | 1206123-37-6 | Ulcerative Colitis (UC) | Under Validation |
| Arginine | 1206123-97-8 | ||
| Fezolinetant | 1629229-37-3 | VMS Caused by Menopause | Under Validation |
| Sparsentan | 254740-64-2 | IgA Nephropathy | Pilot |
| Maralixibat HCl | 228113-66-4 | Cholestatic Itching | Under R&D |
| Capivasertib | 1143532-39-1 | Breast Cancer | Pilot |
掃一掃查看手機版